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Interaction of the mu-opioid receptor with
GPR177 (Wntless) inhibits Wnt secretion:
potential implications for opioid dependence
Jay Jin1, Saranya Kittanakom2, Victoria Wong2, Beverly AS Reyes3, Elisabeth J Van Bockstaele3, Igor Stagljar2†,
Wade Berrettini4†, Robert Levenson1*
Abstract
Background: Opioid agonist drugs produce analgesia. However, long-term exposure to opioid agonists may lead
to opioid dependence. The analgesic and addictive properties of opioid agonist drugs are mediated primarily via
the mu-opioid receptor (MOR). Opioid agonists appear to alter neuronal morphology in key brain regions
implicated in the development of opioid dependence. However, the precise role of the MOR in the development
of these neuronal alterations remains elusive. We hypothesize that identifying and characterizing novel MOR
interacting proteins (MORIPs) may help to elucidate the underlying mechanisms involved in the development of
opioid dependence.
Results: GPR177, the mammalian ortholog of Drosophila Wntless/Evi/Sprinter, was identified as a MORIP in a
modified split ubiquitin yeast two-hybrid screen. GPR177 is an evolutionarily conserved protein that plays a critical
role in mediating Wnt protein secretion from Wnt producing cells. The MOR/GPR177 interaction was validated in
pulldown, coimmunoprecipitation, and colocalization studies using mammalian tissue culture cells. The interaction
was also observed in rodent brain, where MOR and GPR177 were coexpressed in close spatial proximity within
striatal neurons. At the cellular level, morphine treatment caused a shift in the distribution of GPR177 from cytosol
to the cell surface, leading to enhanced MOR/GPR177 complex formation at the cell periphery and the inhibition
of Wnt protein secretion.
Conclusions: It is known that chronic morphine treatment decreases dendritic arborization and hippocampal
neurogenesis, and Wnt proteins are essential for these processes. We therefore propose that the morphine-
mediated MOR/GPR177 interaction may result in decreased Wnt secretion in the CNS, resulting in atrophy of
dendritic arbors and decreased neurogenesis. Our results demonstrate a previously unrecognized role for GPR177
in regulating cellular response to opioid drugs.
Background
Chronic exposure to opioid agonist drugs, such as mor-
phine and heroin, leads to opioid dependence. Opioid
agonists cause pronounced changes in neuronal struc-
ture and synaptic organization, and these may contri-
bute to the drug craving, compulsive drug use, and
analgesic tolerance that characterize the addictive state
[1]. Many of these changes reflect inhibitory growth
effects of morphine and other opioid agonists on neuron
size, neurite outgrowth, dendritic arborization, and neu-
rogenesis that occur in brain regions important for
reward processing, learning, and memory [2-5]. How-
ever, the specific molecular mechanisms that link opioid
agonist activity to the neuronal alterations observed in
opioid dependence remain enigmatic.
Most clinically relevant opioid agonists provide
analgesia via activation of mu-opioid receptors
(MORs), which are members of the G-protein coupled
receptor (GPCR) superfamily [6,7]. In many indivi-
duals, MOR activation also produces a euphoric effect,
which is often considered the primary impetus (or
motivational reward) for abusing opioid drugs [8].
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MOR knockout mice display significantly reduced sen-
sitivity to both the analgesic and rewarding effects of
opioids, thus confirming the importance of the MOR
in analgesia and opioid dependence [9,10]. MORs, like
most GPCRs, are regulated by multiple mechanisms
including receptor desensitization, internalization,
degradation, and recycling [11,12]. A number of stu-
dies have shown that MOR desensitization and traf-
ficking represent key aspects in the development of
opioid tolerance and dependence [8,13-15]. Elucidating
the mechanisms that regulate MOR signaling and traf-
ficking is therefore critical for determining the physio-
logical basis of opioid dependence and enhancing
opioid receptor pharmacology for the treatment of
pain and addiction.
A growing body of evidence indicates that GPCR sig-
naling is modulated by proteins that bind to the GPCR
and form multiprotein signaling complexes or signal-
plexes [16,17]. A number of proteins that interact
directly with the mu-opioid receptor have recently been
identified and shown to affect MOR biogenesis, traffick-
ing, and signaling [17]. For example, periplakin, protein
kinase C interactor1 (PKCI1), and filamin A have all
been found to bind to the C-terminal intracellular tail of
the MOR. Periplakin inhibits G-protein activation when
MOR is bound by an agonist [18], while PCKI1 inhibits
agonist-induced phosphorylation of MOR by G-protein
coupled receptor kinase 2 [19]. After phosphorylation of
MOR, beta-arrestin 2 binds and mediates MOR interna-
lization [20]. Filamin A, on the other hand, serves to
anchor MOR to the cytoskeleton by forming a cross-
bridge with actin [21].
To gain a better understanding of the potential role
of MOR interacting proteins (MORIPs) in mediating
opioid dependence, we propose to delineate novel con-
stituents of the MOR signalplex. Using a modified
split-ubiquitin yeast two-hybrid approach [22-24], we
identified GPR177, a putative orphan GPCR, as a
MORIP. Several recent studies have shown that
GPR177 is the mammalian ortholog of Drosophila
Wntless/Evi/Sprinter, an evolutionarily conserved pro-
tein that plays an important role in secretion of Wnt
proteins from Wnt-producing cells [25-27]. Wnt sig-
naling mechanisms are of particular interest due to
their effects on neuronal development [28]. We find
that in MOR-expressing HEK293 cells, morphine treat-
ment promotes formation of MOR/GPR177 complexes.
This in turn results in sequestration of GPR177 and
inhibition of Wnt protein secretion. Defining the con-
stituents of the MOR signalplex thus represents a criti-
cal step in understanding the mechanisms of MOR-
mediated signaling and the molecular mechanisms
underlying opioid dependence.
Results
Interaction of the μ-Opioid Receptor (MOR) with GPR177
To identify novel MOR interacting proteins (MORIPs),
we performed a modified split-ubiquitin membrane
yeast two-hybrid (MYTH) screen [22-24] using the full-
length MOR as bait. The MYTH screen uses the split-
ubiquitin approach, in which the reconstitution of two
ubiquitin halves is mediated by a specific protein-protein
interaction [29]. We screened 6 × 106 colonies and iso-
lated 104 positive clones representing 10 distinct human
proteins. Two of them were found to encode the C-
terminal domain of GPR177 (residues 451-541). GPR177
is the mammalian ortholog of Drosophila Wntless/Evi/
Sprinter, a putative multi-pass membrane-spanning pro-
tein that is involved in regulating secretion of Wnt pro-
teins from Wnt producing cells [25-27].
Because the split-ubiquitin screen we conducted uti-
lized the entire coding region of the MOR as bait, this
approach provided no information regarding the physi-
cal location of GPR177 binding sites on the receptor.
We therefore used a directed yeast-two hybrid (Y2H)
assay to further test for MOR/GPR177 interactions and
to map the location of GPR177 binding sites on the
MOR. Each of the MOR intracellular loops (IL), includ-
ing the C-terminal domain (C-tail), were used separately
as baits to screen for interaction with the GPR177 clone
identified in the initial split-ubiquitin screen. These
mapping studies, shown in Figure 1, indicate that
GPR177 interacts only with the second intracellular loop
(IL2) of the MOR. We also used the Y2H system to
examine the specificity of the MOR/GPR177 interaction.
In control experiments, the empty prey vector (pACT2)
did not cause autologous activation of the reporter gene.
GPR177 did not interact with the second intracellular
loop of the D2 dopamine receptor (D2IC2), which
shares sequence homology with the MORIL2 at five of
22 positions. Calcium-dependent activator protein for
secretion (CAPS), a previously identified D2IC2-specific
binding protein [30], interacted only with the D2IC2,
but not with any of the MOR intracellular domains
(Figure 1). These results indicate that GPR177 interacts
specifically with the MORIL2 domain in the yeast
system.
To validate the interaction between GPR177 and the
MOR, we tested the ability of GPR177 to associate with
a MORIL2-GST fusion protein in a pulldown assay. As
shown in Figure 2A, a Western blot containing lysate
from bacteria expressing an S-tagged GPR177 cDNA
fragment (encoding residues 451-541) produced an
immunoreactive band of ~18 kDa when probed with
anti-S-tag antibodies. This band corresponds to the
expected size of the C-terminal GPR177 fragment
encoded by the cDNA construct. The same band was
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Figure 1 Directed Y2H screen. The carboxyl-terminus of GPR177 (residues 451-541) was used as bait in a directed Y2H assay for interaction
with each of the intracellular loops (IL) and carboxyl-terminus (C-tail) of the mu-opioid receptor (MOR) and the second intracellular loop of the
D2 dopamine receptor (D2IC2). Full-length CAPS (calcium activated protein for secretion), a known interactor of the D2IC2 was used as a positive
control, and empty bait vector (pACT2) was used as a negative control. A positive interaction is indicated by the production of a blue colony in
the b-gal assay.
Figure 2 GPR177 interacts with MOR. (A) GST Pulldown. A MORIL2-GST fusion protein was used to pull down S-tagged GPR177 C-terminal
fragment from a bacterial lysate. The 18 kDa S-tagged GPR177 fragment produced in bacteria is shown in the lysate lane, while the 18 kDa
S-tagged pull-down product is shown in the pulldown lane. No bands were detectable using beads alone or GST-coated beads. (B)
Coimmunoprecipitation. The MOR was immunoprecipitated from 293-MOR cells overexpressing FLAG/6× His-tagged GPR177 using an anti-MOR
antibody. Immunocomplexes were probed for the presence of GPR177 using chicken anti-GPR177 antibodies. An immunoreactive band of ~50
kDa was detected in the lysate and IP lanes, but not in immunocomplexes from either wild-type HEK293 cells (-MOR lane), 293-MOR cells that
were not transfected with GPR177 (-GPR lane), or in IPs in which no anti-MOR antibodies were added (MOCK lane). (C) Specificity of MOR/
GPR177 interaction. MOR was immunoprecipitated from 293-MOR cells, and the D2 dopamine receptor immunoprecipitated from 293-D2R cells,
using anti-FLAG antibodies. Immunocomplexes were probed for the presence of GPR177 using chicken anti-GPR177 antibodies. For all three
panels, molecular weight markers (kDa) are shown at the left. Data shown is representative of at least five separate experiments.
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detected by pulldown after the bacterial lysate was incu-
bated with the MORIL2-GST fusion protein, but not
when the lysate was absorbed onto beads alone or GST-
coated beads.
The interaction between full-length MOR and GPR177
was verified in co-immunoprecipitation (CoIP) experi-
ments. To demonstrate interaction, we tested the ability
of an anti-MOR antibody to coimmunoprecipitate
GPR177 from lysates prepared from HEK293 cells stably
expressing FLAG-tagged MORs (293-MOR cells) and
transiently transfected with a FLAG/6× His-tagged
GPR177 construct. 293-MOR cells were a generous gift
from Dr. Mark von Zastrow (UCSF). Preliminary Wes-
tern blot analysis (Additional file 1, Figure S1A) revealed
that the anti-MOR antibody specifically immunoprecipi-
tated (IP) the mu-opioid receptor from 293-MOR cells.
Lysates from transfected cells were immunoprecipitated
using the anti-MOR antibody, and immunocomplexes
probed with chicken anti-GPR177 antibodies. As shown
in Figure 2B, an immunoreactive band of ~50 kDA, the
predicted size of GPR177, was detected in lysates pre-
pared from transfected cells with the anti-GPR177 anti-
body. A band migrating with the identical molecular
mass was detected in the IP lane, but not in IPs from
cells lacking MOR expression (-MOR lane), IPs from
293-MOR cells not transfected with GPR177 (-GPR
lane), or mock IPs (mock lane). The specificity of the
anti-GPR177 antisera was ascertained by transfecting a
FLAG/6× His-tagged GPR177 cDNA into HEK293 cells.
A Western blot containing lysate prepared from trans-
fected cells was first probed with anti-FLAG antibodies,
then stripped and reprobed with anti-GPR177 antibo-
dies. A band migrating with the identical molecular
mass was detected with anti-FLAG and anti-GPR177
antibodies (Additional file 1, Figure S1B), indicating that
the GPR177 antibodies react specifically with GPR177.
To examine the specificity of the MOR/GPR177 inter-
action, we asked whether GPR177 could be coimmuno-
precipitated from 293-D2R cells. 293-D2R cells (gift
from Dr. Mark von Zastrow) stably express FLAG-
tagged D2Rs but not the MOR, and endogenously
express GPR177. As shown in Figure 2C, when lysates
from 293-MOR cells were immunoprecipitated with
anti-FLAG antibodies and immunocomplexes probed
with the anti-GPR177 antibody, we detected an immu-
noreactive band of ~45 kDa. This band corresponds to
the size expected for endogenously expressed GPR177
(lacking the FLAG/6 × His tag). In contrast, when
lysates prepared from 293-D2R cells were immunopreci-
pitated with anti-FLAG antibodies, we were unable to
detect any immunoreactive bands corresponding to
GPR177 when the immunocomplexes were probed
using anti-GPR177 antibodies. Taken together, our data
strongly suggests that GPR177 interacts specifically with
the MOR through the interaction of the carboxy-termi-
nus of GPR177 with the second intracellular loop of the
MOR. In the future, direct binding of these two proteins
can be established using biophysical-type approaches.
MOR and GPR177 Interact in PC12 Cells and Rat Brain
To further characterize the GPR177/MOR interaction,
we examined expression of GPR177 in rat pheochromo-
cytoma (PC12) cells and rat brain. Western blotting
experiments revealed endogenous expression of GPR177
polypeptides in PC12 cell and rat brain lysates (Figure
3), while PC12 cells have previously been shown to
express MORs [31,32]. CoIP experiments were therefore
performed to test whether endogenously expressed
GPR177 and MORs are associated in PC12 cells and rat
brain. To do this, MORs were immunoprecipitated from
either PC12 cells or rat brain with anti-MOR antibodies,
and immunocomplexes probed for the presence of
GPR177. In PC12 cells, anti-GPR177 antibodies reacted
with an ~48 kDa band in the lysate and IP lanes, but
not in mock immunoprecipitations in which anti-MOR
antibodies were omitted (Figure 3A). In rat brain, Wes-
tern blot analysis revealed the presence of an ~48 kDa
band in the lysate and IP lanes, but not in mock immu-
noprecipitations or immunoprecipitations using non-
specific anti-FLAG antibodies (Figure 3B). These results
indicate that endogenously expressed GPR177 and
MORs interact in PC12 cells as well as rat brain.
MOR and GPR177 Colocalize in Striatal Neurons
We next used a combination of immunofluorescence
and immunoelectron microscopy to analyze the cellular
and subcellular distribution of GPR177 and the MOR in
mouse striatum. In double-labeling experiments with
anti-GPR177 and anti-MOR antibodies, somatodendritic
processes exhibiting coexpression of GPR177 (red) and
MOR (green) proteins were localized to common cellu-
lar profiles in striatum (Figure 4A-C). These observa-
tions suggest that GPR177 colocalizes with the MOR in
a subpopulation of striatal neurons.
Double immunoelectron microscopic analysis was
used to gain insight into the subcellular distribution of
GPR177 and the MOR. For these ultrastructural studies,
peroxidase labeling was used to localize MORs and
immunogold-silver labeling was used to localize
GPR177. As shown in Figure 4D, peroxidase labeling for
the MOR was visualized as a diffuse reaction product
that was associated with the plasmalemma and cytoplas-
mic portions of dendritic processes. GPR177 immunor-
eactivity, visualized as irregularly shaped black deposits
indicative of immunogold-silver labeled particles (Figure
4D), exhibited a predominantly cytoplasmic localization.
Expression of GPR177 and the MOR in striatal sec-
tions was also analyzed using dual immunogold labeling.
Jin et al. BMC Neuroscience 2010, 11:33
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As shown in Figure 4E-F, the MOR was identified by
large (> 0.05 μm cross-sectional diameter) immunogold-
silver particles and GPR177 by smaller (< 0.05 μm
cross-sectional diameter) immunogold-silver particles. In
double-labeling experiments, GPR177 and MOR immu-
noreactivity was found in some cases to colocalize in
perikarya (Figure 4E) and in dendritic processes (Figure
4F). Within double-labeled structures, some of the
immunometal particles representing MOR and GPR177
were situated in close proximity to one another either in
the cytoplasm or at the plasma membrane. Taken
together, our immunofluorescence data indicate that
GPR177 and MORs are coexpressed within the same
striatal neuron. The close spatial proximity of the MOR
and GPR177 revealed by immunoelectron microscopy
provides additional evidence supporting an interaction
between these two proteins within neurons.
Exposure to Opioid Agonists Promotes Formation of
MOR/GPR177 Complexes
To investigate the effect of opioid agonists on MOR/
GPR177 complex formation, we first used confocal laser
microscopy to examine the distribution of MOR and
GPR177 polypeptides in 293-MOR cells treated with
10 μM morphine for one hour. In untreated and mor-
phine-treated 293-MOR cells, MORs were localized pre-
dominantly at the plasma membrane (Figure 5A, left-
hand panels). In both untreated and morphine-treated
cells, staining for GPR177 was also detected at the per-
iphery, although a considerable amount of GPR177 stain-
ing appeared cytosolic (Figure 5A, middle panels). In
cells treated with morphine, we observed an increase in
MOR/GPR177 colocalization (Figure 5A, merged
images), suggesting that morphine treatment may cause
an increase in the association between the MOR and
GPR177. The distribution of MOR and GPR177 polypep-
tides in cells treated with 10 μM DAMGO, however, was
considerably different. After a one hour exposure period,
both the MOR (bottom left panel) and GPR177 (bottom
middle panel) appeared to be internalized and staining
was predominantly cytosolic. The merged image (bottom
right panel) indicates that the bulk of MOR/GPR177
complexes colocalized within cytosolic compartments.
To examine the effect of opioid agonists on the MOR/
GPR177 interaction in greater detail, we used coimmu-
noprecipitation to investigate whether opioid treatment
promotes MOR/GPR177 complex formation. In these
experiments, 293-MOR cells were exposed to 10 μM
Figure 3 Interaction of MOR and GPR177 in PC12 cells and rat brain. (A) Lysates prepared from PC12 cells were immunoprecipitated with
anti-MOR antibodies. (B) Lysates were prepared from total rat brain and immunoprecipitated with anti-MOR antibodies. In A and B,
immunocomplexes were separated by SDS-PAGE, transferred to a PVDF filter, and filters probed with anti-GPR177 antibodies. Molecular weight
markers (kDa) are shown at the left. The upper band in rat brain lysates is non-specific. Data shown is representative of at least three separate
experiments.
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morphine or 10 μM DAMGO for one hour. Total cellu-
lar lysates were prepared, and the MOR immunoprecipi-
tated using an anti-MOR antibody. Immunocomplexes
were then probed for GPR177 with chicken anti-
GPR177 antibody. As shown in Figure 5B, MORs were
associated with GPR177 under basal conditions, and
MOR/GPR177 complex formation appeared to be signif-
icantly increased after treatment with morphine or
DAMGO. Morphine-induced MOR/GPR177 complex
formation was not accompanied by an increase in
expression of GPR177 polypeptides (data not shown).
Together, these results suggest that both morphine and
DAMGO increase MOR/GPR177 complex formation.
Further, morphine treatment appears to cause a shift in
the distribution of GPR177 from cytosol to the cell sur-
face. This redistribution permits enhanced MOR/
GPR177 complex formation at the cell periphery.
DAMGO, on the other hand, results in MOR internali-
zation, thus leading to an increased association between
the MOR and GPR177 within the cytosol.
Effect of MOR/GPR177 Interaction on Wnt secretion
Recent studies have shown that GPR177 plays an essen-
tial role in mediating Wnt protein secretion from
Wnt-producing cells [25-27]. We therefore wished to
determine whether the interaction between GPR177 and
MOR might contribute to the regulation of Wnt secre-
tion. To test this idea, we examined Wnt secretion
Figure 4 MOR and GPR177 colocalize within mouse striatum. Region of the striatum selected for immunohistochemical analysis is shown in
the inset of Panel A. (A-C) Confocal images of immunolabeling of GPR177 (red) and MOR (green) within striatum. Arrowheads in A indicate
GPR177 immunolabeling; arrowheads in B indicate MOR immunolabeling; arrowheads in C (merged image) indicate colocalization of the two
proteins. Thin arrows (A and C) indicate a cell expressing only GPR177, whereas thick arrows (B and C) indicate a cell expressing only MOR.
Arrows in lower left corner of panel A indicate dorsal (D) and lateral (L) orientations. Scale bar = 0.05 μm. (D) Electron photomicrograph
showing immunogold-silver (GPR177; arrowheads) and immunoperoxidase (MOR; arrows) labeling within a dendritic process in mouse striatum.
An unlabeled terminal (ut) forms a synaptic contact with a dendrite double-labeled for GPR177 and MOR (MOR-d). Scale bar = 50 μm. (E-F)
Electron photomicrographs showing dual immunogold-silver-labeled GPR177 (arrowheads) and MOR (arrows) within a perikaryon (E) and
dendrite (F) within mouse striatum. Scale bar = 0.5 μm. er: Endoplasmic reticulum; Nu: Nucleus; m: Mitochondria.
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Figure 5 Effect of opioid agonists on MOR/GPR177 interaction. (A) 293-MOR cells were grown either in the absence of drugs (upper
panels), or in the presence of 10 μM morphine (middle panels) or 10 μM DAMGO (lower panels) for one hour. Cells were stained with anti-MOR
(red) and anti-GPR177 (green) antibodies. Merged images are shown in the right-hand panels. (B) 293-MOR cells were treated with agonist as in
A. Cell lysates were immunoprecipitated with anti-MOR antibodies, and immunocomplexes probed with anti-GPR177 antibodies. The bands were
analyzed by densitometry and quantitated using ImageJ software. Open bars represent untreated cells, black bars represent morphine-treated
cells, and grey bars represent DAMGO-treated cells. Data was analyzed using paired Student’s t-test (expressed as mean ± SEM; n = 3, *p < 0.01).
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utilizing HEK293 cells, which do not normally express
Wnt proteins, but do secrete Wnt polypeptides after
transient transfection with Wnt cDNA [25,26]. As
shown in Figure 6 (panels A-D), wild-type HEK293,
293-MOR, and 293-D2R cells are all capable of secreting
Wnt2 polypeptides after transient transfection with myc-
tagged Wnt2 cDNA. Treatment of wild-type HEK293
cells with morphine or DAMGO produced no signifi-
cant effect on Wnt2 secretion compared to untreated
cells (Figure 6A). However, treatment of 293-MOR cells
with morphine produced a significant decrease in Wnt2
secretion compared to untreated controls (Figure 6B).
The inhibition of Wnt secretion appears to be specific
to the activation of MORs by morphine, since DAMGO
did not affect Wnt2 secretion from 293-MOR cells
(Figure 6B). Further, dopamine treatment did not signi-
ficantly affect Wnt2 secretion from D2 dopamine recep-
tor-expressing 293-D2R cells (Figure 6C).
Figure 6 Morphine inhibits Wnt secretion. Wild-type HEK293 (A) and 293-MOR cells (B) were transfected with myc-tagged Wnt2 cDNA.
24 hours after transfection, cells were treated with either 10 μM morphine or 10 μM DAMGO for an additional 24 hours. In A and B, open bars
represent non-drug-treated controls, black bars represent morphine-treated cells, and grey bars represent cells treated with DAMGO. (C) 293-D2R
cells were transfected and processed as in A and B, but were cultured in the presence of 10 μM dopamine instead of morphine. Media was
collected, proteins separated by SDS-PAGE, then transferred to a PVDF filter. Filters were probed with anti-myc antibodies. Open bars represent
non-drug-treated controls, black bars represent drug-treated cells. (D) Overexpression of GPR177 rescues Wnt secretion. 293-MOR cells were
transfected with myc-tagged Wnt2 and GPR177 cDNAs. Cells were processed and proteins visualized as described above. Open bars represent
no drug treatment, black bars represent morphine-treated cells, and grey bars represent cells overexpressing GPR177. Bands were analyzed by
densitometry and quantitated using ImageJ software. Data was analyzed using a two-sided Student’s t-test (expressed as mean ± SEM; n= 4-5;
*p < 0.05; **p < 0.01).
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We next asked whether the morphine-mediated inhi-
bition of Wnt2 secretion could be reversed by overex-
pression of GPR177. To do this, we cotransfected 293-
MOR cells with myc-tagged Wnt2 and GPR177 cDNAs,
and monitored Wnt2 secretion in cells grown in the
presence or absence of morphine. As shown in Figure
6D, morphine treatment caused a significant inhibition
of Wnt2 secretion compared to untreated controls.
However, overexpression of GPR177 in morphine-trea-
ted 293-MOR cells produced a dramatic increase in
Wnt2 secretion. Taken together, the data from these
experiments strongly suggests that morphine treatment
specifically blocks Wnt secretion from MOR expressing
cells, and that this inhibition can be overcome by over-
expression of GPR177.
To confirm that the inhibition of Wnt2 secretion by
morphine is regulated through the mu-opioid receptor,
we tested the ability of the potent MOR antagonists
CTAP [33] and naloxone [34], to block the morphine-
mediated effect. In these experiments, 293-MOR cells
were pretreated with either CTAP or naloxone for one
hour prior to the addition of morphine and the initia-
tion of the secretion assay. As shown in Figure 7, pre-
treatment with either CTAP or naloxone reversed the
morphine-mediated inhibition of Wnt2 secretion. These
results provide compelling evidence that the morphine-
mediated inhibition of Wnt2 secretion is regulated via
the mu-opioid receptor.
Discussion
In this study, we demonstrate that mu-opioid receptors
(MORs) can functionally interact with GPR177, an evo-
lutionarily conserved protein that mediates Wnt protein
secretion in a variety of species including flies, worms,
frogs, rodents, and humans [35-37]. Through its interac-
tion with the MOR, GPR177 appears to play an impor-
tant physiological role in neuronal response to opioid
agonists. This interpretation is based on the following
conclusions. First, the MOR/GPR177 interaction occurs
within neurons. Second, the association between these
two proteins is enhanced by morphine treatment. Third,
an increase in the interaction between the MOR and
GPR177 results in the inhibition of Wnt secretion.
These findings shed new light on the role of MORIPs in
the neurobiology of opioid agonist actions, and offer a
mechanism whereby chronic opioid agonist exposure
may produce deleterious effects on neuronal structure
and function via inhibition of Wnt secretion.
The interaction between the MOR and GPR177 was
initially uncovered in a MYTH screen and then vali-
dated in GST-pulldown and coimmunoprecipitation
assays. To our knowledge, this represents the first suc-
cessful MYTH screen using a full-length human GPCR
as bait. The potential physiological relevance of the
MOR/GPR177 interaction is borne out by the data in
Figures 3 and 4. The coimmunoprecipitation results pre-
sented in Figure 3 indicate that MORs and GPR177
endogenously expressed within cultured cells and brain
tissue are capable of interacting with each other. The
double-label light and immunoelectron microscopic ana-
lysis shown in Figure 4 further establish that MOR and
GPR177 are coexpressed within a subset of striatal neu-
rons. The close spatial proximity of MOR and GPR177
immunoreactivity within perikarya and dendrites pro-
vides compelling evidence for an interaction between
these two proteins within striatal neurons. Since
Figure 7 Effect of MOR antagonists on Wnt secretion. 293-MOR cells were transfected with myc-tagged Wnt2 cDNA. 24 hours after
transfection, cells were treated with either (A) 10 μM CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) or (B) 10 μM naloxone for one hour
followed by an additional 23 hours of treatment with 1 μM morphine. Media was collected, proteins separated by SDS-PAGE, then transferred to
a PVDF filter. Filters were probed with anti-myc antibodies and immunoreactive bands scanned by laser densitometry and quantitated using
ImageJ software. In A and B, open bars represent untreated 293-MOR cells, black bars represent 293-MOR cells treated with morphine, and grey
bars represent 293-MOR cells treated with either CTAP plus morphine or naloxone plus morphine. Data was analyzed using a two-sided
Student’s t-test (expressed as mean ± SEM; n= 5-6; *p < 0.05).
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GPR177 and MOR are widely expressed in rodent and
human brain (unpublished observations) it is likely that
the MOR/GPR177 interaction occurs in many brain
regions.
Our analysis of the effect of opioid agonists on MOR/
GPR177 complex formation, together with the Wnt
secretion experiments, indicate that the MOR/GPR177
interaction is likely to be of importance for understand-
ing the changes that occur in brain after chronic opioid
use. We now propose a model (Figure 8) in which the
MOR/GPR177 interaction regulates the secretion of
Wnt proteins that are required for neuronal develop-
ment and morphogenesis. This model is based on the
following lines of evidence. GPR177 is a protein that
mediates Wnt secretion in a variety of vertebrate and
invertebrate species [35]. GPR177 has also been shown
to regulate Wnt secretion in cultured Drosophila and
mammalian cells [25,26]. Using immunohistochemistry
and coimmunoprecipitation, we found that the level of
MOR/GPR177 complexes was significantly increased
after treatment of 293-MOR cells with morphine. This
observation is consistent with data reported in other
systems. In mice, for example, opioid agonist activation
of MOR causes a significant increase in the association
of MOR with spinophilin, a dendritic spine-enriched
scaffold protein [38].
Our data indicate that MOR and GPR177 are binding
partners, and their association with one another occurs
in cytosolic compartments as well as at the cell surface.
GPR177 has previously been shown to interact with
Wnt proteins in the Golgi, and the two proteins traffic
together to the plasma membrane where Wnt proteins
are then secreted [25]. GPR177 is internalized via cla-
thrin-mediated endocytosis and recycled back to the
Golgi via the retromer complex [39,40]. In the Wnt
secretion experiments we performed, treatment of wild-
type HEK293 cells with either morphine or DAMGO
produced no significant effect on Wnt secretion com-
pared to untreated control cells (Figure 6A). In
untreated 293-MOR cells (Figure 6B), the MOR/
GPR177 interaction that takes place under basal condi-
tions does not appear to interfere either with the ability
of GPR177 to mediate Wnt secretion nor with normal
GPR177 trafficking.
When cells are treated with morphine, however, the
situation is quite different. Our results indicate that
morphine application appears to cause a redistribution
of GPR177 from cytosol to the cell surface and
enhanced MOR/GPR177 complex formation at the cell
periphery. In morphine-treated 293-MOR cells, this
leads to an inhibition of Wnt secretion (Figure 6B).
Since it is well established that morphine application
leads to delayed MOR internalization [41-45], we
hypothesize that the morphine-enhanced interaction
between MOR and GPR177 causes entrapment of
GPR177 at the cell surface, effectively sequestering
GPR177 and inhibiting its proper function in mediating
Wnt secretion. We propose that when MOR is bound
to GPR177, GPR177 is unable to shuttle Wnt proteins
between the Golgi and the cell surface (Figure 8B).
Figure 8 Proposed model for effect of MOR/GPR177interaction on Wnt secretion. (A) Under basal conditions, MOR and GPR177 are
associated at the plasma membrane (PM) and in recycling vesicles (V). However, GPR177 is located primarily in vesicles in association with Wnts,
whereas MOR is predominantly plasma membrane-associated. Recycling of GPR177 from PM to Golgi (G) is mediated via retromer, and is
required for Wnt secretion. (B) In the presence of morphine, MORs are inefficiently internalized which leads to an increase in the association
between MOR and GPR177 near the plasma membrane. This results in reduced retromer-mediated GPR177 recycling and functional
sequestration of GPR177 activity. Reduced recycling of GPR177 leads to inhibition of Wnt secretion. (C) In the presence of DAMGO, MORs are
efficiently internalized which allows for internalization of GPR177 proteins associated with MORs. Once internalized, GPR177 is recycled to the
Golgi apparatus via retromer, thereby allowing GPR177 to associate with Wnt proteins and functionally support Wnt protein secretion.
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However, as has been shown previously, DAMGO appli-
cation leads to fast internalization of MORs [41,43,45].
Thus, DAMGO treatment may allow for rapid internali-
zation of GPR177. In our model (Figure 8C), we propose
that following DAMGO treatment, MOR/GPR177 com-
plexes internalize from clathrin-coated pits into early
endosomes. After internalization, MOR/GPR177 com-
plexes dissociate, and GPR177 is recycled to the Golgi
via association with the retromer complex. In the Golgi,
GPR177 is able to associate with Wnt proteins that are
then targeted to the plasma membrane for secretion
[25-27]. Because GPR177 cycling is likely to be main-
tained in the presence of DAMGO, there is no signifi-
cant effect of DAMGO on Wnt secretion.
Our data demonstrate a previously unrecognized role
for GPR177, a novel MORIP, in regulating cellular
response to opioid agonist drugs. Morphine treatment
induces cell-surface associated MOR/GPR177 complex
formation which in turn inhibits Wnt protein secretion.
Wnt proteins have been known for some time to play
an essential role in morphological patterning during
development [46]. New roles for these proteins have
also been discovered in stem cell maintenance [47,48],
cancer biology [49], as well as neuronal development
[28] and synaptic remodeling [50,51]. In brain, Wnt3
has been shown to regulate neurogenesis in hippocam-
pus [52], while Wnt7b mediates dendritic arborization
[53]. These processes are known to be severely compro-
mised after chronic morphine exposure [4,54]. Our dis-
covery of an interaction between the MOR and GPR177
may thus represent an important conceptual break-
through in understanding the mechanism whereby
opioid agonist drugs produce these profound morpholo-
gical changes in brain. The loss of dendritic arborization
and/or neurogenesis may be key to understanding the
myriad problems associated with opioid use including
addiction, cognitive dysfunction, depression, and
impaired visual and motor skills. Clearly, the ability to
determine the influence of GPR177 on the acute and
chronic actions of opioids will require the development
of appropriate mouse models in which the effect of dis-
rupting the GPR177 gene can be analyzed in behavioral
paradigms of opioid agonist action. The molecular
actions of GPR177 suggest that it could serve as a novel
drug target that could be utilized to promote analgesia
while preventing the deleterious neuronal alterations
that accompany chronic opioid agonist use.
Conclusions
In this study, we demonstrate an interaction between
the MOR and GPR177, an evolutionarily conserved pro-
tein that regulates secretion of Wnt proteins in Wnt-
producing cells. The interaction between these two
binding partners is enhanced by treatment of cells with
opioid agonist drugs, and results in the inhibition of
Wnt protein secretion. Based on these findings, we pro-
pose a model in which opioid agonist inhibition of Wnt
protein secretion is responsible for the loss of dendritic
arborization and neurogenesis that occurs after chronic
opioid exposure. These findings suggest a previously
unrecognized role for GPR177 in regulating cellular
response to opioid agonist drugs, and could create new
avenues of investigation regarding the pharmacotherapy
of drug dependence.
Methods
Split-Ubiquitin Membrane and Conventional Yeast
Two-Hybrid Screens
A modified split-ubiquitin membrane yeast two-hybrid
(MYTH) screen was performed as previously described
[22-24]. Briefly, full-length human MOR cDNA in the
bait vector pCCW-STE (Dualsystems Biotech AG, Swit-
zerland) and human fetal brain cDNA library in the
prey vector pPR3-N (Dualsystems) were sequentially
transformed into S. cerevisiae reporter strain THY.AP4.
Transformation of yeast with the human brain library
produced 6 × 106 transformants/μg DNA on synthetic
dropout (SD) agar plates (-Trp/-Leu/-His/-Ade; Clon-
tech, Palo Alto, CA) containing 3-amino-1,2,4-triazole
(3AT). From this screen we identified 10 novel MORIPs,
two of which contained cDNAs encoding the C-terminal
tail (residues 451-541) of GPR177.
To identify sites of interaction between MOR and
GPR177, each MOR intracellular loop (IL) was tested for
interaction with the carboxyl-terminus of GPR177 using
the conventional yeast two-hybrid (Y2H) method. MOR
IL domains (IL1, residues 97-103; IL2, residues 166-187;
IL3, residues 260-282; C-tail, residues 342-400) were
separately ligated into the yeast GAL4 DNA-binding
domain vector pAS2-1 (Clontech), while the carboxyl-
terminus of GPR177 (GPR177-CT: residues 451-541) was
ligated into the yeast GAL4 activation domain vector
pACT2 (Clontech). Bait and prey plasmids were simulta-
neously cotransformed into S. cerevisiae strain MAV103
as previously described [55]. Transformants were identi-
fied by growth on SD/-Trp/-Leu agar plates. Interactions
were assayed for b-galactosidase activity via the nitrocel-
lulose filter lift method [55].
Cell Culture and Drug Treatment
Human Embryonic Kidney (HEK) 293 cells and rat
pheochromocytoma (PC12) cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with 10% fetal bovine serum. FLAG-tagged
MOR expressing HEK293 (293-MOR) cells and FLAG-
tagged D2 dopamine receptor (D2R) expressing HEK293
(293-D2R) cells were provided by Dr. Mark von Zastrow
(University of California, San Francisco) and maintained
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in DMEM supplemented with 10% fetal bovine serum
and 400 μg/ml geneticin (Invitrogen, Carlsbad, CA).
Transfections were carried out using Effectene transfec-
tion reagent (Qiagen, Valencia, CA) according to manu-
facturer’s instructions. Morphine sulfate (10 μM; Baxter
Healthcare, Deerfield, IL), [D-Ala2, N-MePhe4, Gly-ol]-
enkephalin (DAMGO, 10 μM; Sigma, St. Louis, MO),
and dopamine (10 μM; Sigma) were diluted directly into
cell culture medium.
Antibody Production and Immunocytochemistry
Anti-GPR177 antibodies were raised in chickens
against a peptide antigen corresponding to the C-term-
inal 18 amino acids (HVDGPTEIYKLTRKEAQE) of
human GPR177 (Gene-Tel Laboratories, Madison, WI).
Antibodies of the IgY subtype were harvested from egg
yolks and affinity purified prior to use. For immunocy-
tochemistry, 293-MOR cells were grown on poly-L-
lysine (Sigma) coated coverslips for 24 hours, treated
with drug for one hour, then fixed with 4% parafor-
maldehyde for 15 minutes. Cells were washed 3 times
with phosphate-buffered saline (PBS) then incubated
with blocking solution (5% goat serum, 0.1% Triton
X-100, 1× PBS) for 1 hour at room temperature. Dou-
ble labeling was performed by incubation with rabbit
anti-MOR (AB5511; 1:500 dilution; Millipore, Bedford,
MA) and chicken anti-GPR177 (1:500 dilution) antibo-
dies. Double staining was visualized with Cy3-conju-
gated goat anti-rabbit (1:500 dilution, Jackson
ImmunoResearch, West Grove, PA) and fluorescein
isothiocyanate (FITC)-conjugated goat anti-chicken
antibodies (1:500 dilution, Jackson ImmunoResearch).
Fluorescent images were captured on a Leica TCS SP2
AOBS confocal microscope.
Glutathione S-transferase Pull-Down and
Coimmunoprecipitation
A MORIL2-GST (glutathione S-transferase) fusion pro-
tein was constructed by fusing amino acids 166-187 of
the human MOR to GST in the expression vector
pGEX-4T-1 (Amersham Biosciences, Piscataway, NJ).
The MORIL2-GST-fusion protein was induced in
Escherichia coli strain BL21 (DE3) using the ZYP-5052
auto-induction media described previously [56,57]. The
GPR177 C-terminal fragment (residues 451-541) was
subcloned into the pET30C expression vector containing
an S-tag. Constructs were induced using auto-induction
media as described above. MORIL2-GST fusion protein
was used to pull down the GPR177 C-terminal fragment
from bacterial lysates as previously described [55].
Eluted proteins were separated by SDS-PAGE and trans-
ferred to a polyvinylidene fluoride (PVDF) filter. The fil-
ter was probed with a horseradish peroxidase (HRP)
conjugated S-tag antibody (1:5000 dilution, Novagen,
Madison, WI), and immunoreactivity detected by
enhanced chemiluminescence with an ECL Plus kit (GE
Healthcare, Piscataway, NJ)
For coimmunoprecipitation experiments, a full-length
GPR177 cDNA containing an N-terminal 6× histidine
(His) tag was ligated into the pCMV-Tag2 mammalian
expression vector, and the construct transfected into
293-MOR cells. Immunoprecipitations were performed
from total cell lysates as previously described [58].
MORs were immunoprecipitated from lysates using an
anti-MOR antibody (AB1580, Millipore). Western analy-
sis of immunoprecipitated complexes was performed by
using polyclonal anti-GPR177 antibody (1:5000 dilution).
Staining was visualized with a 1:15,000 dilution of HRP-
conjugated donkey anti-chicken secondary antibodies
(Jackson ImmunoResearch).
Wnt2 secretion assay
HEK293, 293-MOR, or 293-D2R cells were separately
transfected with a myc-tagged human Wnt2 cDNA in
the pCMV-Tag3 mammalian expression vector (Strata-
gene, La Jolla, CA). Cells were grown in DMEM plus
10% FBS for 24 hrs, then grown in the presence or
absence of 10 μM morphine, 10 μM DAMGO, or 10
μM dopamine in DMEM lacking FBS, for an additional
24 hrs prior to initiating secretion assays. To assess
secretion, medium was collected and concentrated
(approximately 22-fold) using an Amicon Ultra-15 cen-
trifugal filter (Millipore). Aliquots of medium (45 μl)
were fractionated on SDS-containing 10% polyacryla-
mide gels. Proteins were transferred to a PVDF mem-
brane, and the filter probed with a monoclonal anti-myc
antibody (1:2500 dilution; Millipore). Proteins were
visualized using HRP-conjugated rabbit-anti-mouse sec-
ondary antibodies (1:15,000 dilution; Jackson ImmunoR-
esearch). Immunoreactivity was detected by ECL using
an ECL Plus kit, and scanned blots quantitated using
the ImageJ software package (NIH). Data were subjected
to a two-tailed Student’s t-test.
Immunofluorescence Microscopy
Mice used for immunohistochemistry were housed and
treated according to institutional guidelines. Adult male
mice were perfused with 50 ml of 4% formaldehyde in
0.1 M PB; pH 7.4, and brains were removed and post-
fixed in 4% formaldehyde overnight at 4°C. Striatal sec-
tions (40 μm) were rinsed extensively in 0.1 M PB and
0.1 M tris-buffered saline (TBS; pH 7.6), incubated in
0.5% bovine serum albumin (BSA) and 0.25% Triton X-
100 in 0.1 M TBS for 30 min, then rinsed extensively in
0.1 M TBS. Sections were incubated with a cocktail con-
taining chicken anti-GPR177 (1:1,000 dilution) and rab-
bit anti-MOR (1:2,000 dilution; Immunostar Inc.,
Hudson, WI) antibodies. Sections were washed in 0.1 M
Jin et al. BMC Neuroscience 2010, 11:33
http://www.biomedcentral.com/1471-2202/11/33
Page 12 of 15
TBS, then incubated in a cocktail containing Alexafluor
488 donkey anti-rabbit (1:80 dilution; Jackson Immu-
noResearch) and tetramethyl rhodamine isothiocyanate
(TRITC) donkey anti-chicken (1:200 dilution; Jackson
ImmunoResearch) secondary antibodies. Fluorescent
images were obtained with a confocal microscope (Zeiss
LSM 510 Meta, Carl Zeiss Inc., Thornwood, NY), and
digital images were captured and imported with the
LSM 5 image browser (Carl Zeiss Inc.).
Immunoelectron Microscopy
Mice were perfused with (1) 10 ml heparinized saline,
(2) 50 ml of 4% formaldehyde in 0.1 M PB, pH 7.4.
Immediately after perfusion, brains were removed, sec-
tioned into coronal slices and postfixed overnight at 4°C
in the same fixative. Alternate 40 μm thick sections
through the rostrocaudal extent of the striatum were
incubated with a cocktail of chicken anti-GPR177
(1:1,000 dilution) and rabbit anti-MOR (1:2,000 dilution)
antibodies. Immunoperoxidase labeling was used to
identify MOR immunoreactivity while immunogold-sil-
ver labeling was used to identify GPR177. Primary anti-
bodies were complexed with a mixture of biotinylated
donkey anti-rabbit (1:400 dilution; Jackson ImmunoRe-
search) and ultra small (< 1 nm) gold-coupled goat anti-
chicken (1:100 dilution; Electron Microscopy Sciences,
Fort Washington, PA) secondary antibodies. MOR was
detected by incubation with avidin-biotin complex (Vec-
tor Laboratories, Burlingame, CA) and visualized by
DAB (3,3’-diaminobenzidine; Sigma). To visualize
immunogold-labeled GPR177, silver enhancement of the
gold particles was performed using a silver enhancement
kit (Amersham Bioscience, Piscataway, NJ). Sections
were flat embedded in Epon 812 (Electron Microscopy
Sciences). Thin sections (50-100 nm) were collected on
copper mesh grids and examined with an electron
microscope (Morgagni Fei Company, Hillsboro, OR).
Digital images were captured using an AMT advantage
HR/HR-B CCD camera system (Advance Microscopy
Techniques Corp., Danvers, MA).
For dual immunogold labeling, 40 μm sections through
the rostrocaudal extent were incubated in a cocktail con-
taining chicken anti-GPR177 (1:1,000 dilution) and rabbit
anti-MOR (1:2,000 dilution) primary antibodies. Sections
were incubated with ultra small gold-coupled goat anti-
rabbit (1:100 dilution; Amersham Bioscience) secondary
antibody, followed by the first silver enhancement (300 μl
R-Gent SE-EM enhancement mixture; Amersham
Bioscience). Sections were then incubated with ultra
small gold-coupled goat anti-chicken (1:100 dilution;
Amersham Bioscience) secondary antibody, followed by
the second silver enhancement (300 μl R-Gent SE-EM
enhancement mixture; Amersham Bioscience). Immuno-
gold-silver particles measuring less than 0.05 μm in
cross-sectional diameter were scored as small, while
immunogold-silver particles measuring greater than
0.051 μm were scored as large. Tissues sections were
incubated in 2% osmium tetroxide (Electron Microscopy
Sciences) and flat embedded in Epon 812. Digital image
capturing was as described above.
Additional file 1: Figure S1 - Specificity of anti-MOR and anti-
GPR177 antibodies. (A) Specificity of anti-MOR antibodies. 293-MOR
cells, stably expressing FLAG-tagged MORs, were transiently transfected
with a FLAG/6x His-tagged GPR177 construct. Lysates were
immunoprecipitated with anti-MOR antibodies (Millipore).
Immunocomplexes were separated by SDS-PAGE, transferred to a PVDF
filter, and filters probed with M2 anti-FLAG monoclonal antibodies.
Molecular weight markers (kDa) are shown at the left. The transfected
GPR177 was detected in the lysate lane, while both GPR177 and the
MOR were detected in the IP lane. MORs were also detected in IPs from
untransfected 293-MOR cells (-GPR177 lane). No immunoreactive bands
were detected in IPs from wild-type HEK293 cells (lacking MORs)
transiently transfected with GPR177 (-MOR lane) or in IPs of transiently
transfected 293-MOR cells in which anti-MOR antibodies were omitted
(Mock lane). (B) Specificity of anti-GPR177 antibodies. Lysates were
prepared from 293-MOR cells (293-MOR lysate lanes) and 293-MOR cells
transiently transfected with a FLAG/6x His-tagged GPR177 construct
(+FLAG/His GPR177 lanes). The immunoblot was initially probed with M2
anti-FLAG antibodies (left panel). The blot was then stripped and
reprobed with anti-GPR177 antibodies (right panel). Molecular weight
markers (kDa) are shown at the left. A band migrating with the identical
molecular mass was detected with M2 anti-FLAG and anti-GPR177
antibodies, indicating that GPR177 antibodies react specifically with
GPR177.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2202-11-
33-S1.TIFF ]
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